



Novel Vaccine Stabilization and Delivery Technologies: Edition II

Guest Editors:

Prof. Dr. Martin J. D'Souza

Dr. Mohammad N. Uddin

Dr. Rikhav Gala

Dr. Bernadette D'Souza

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editors

To formulate effective prophylactic or therapeutic vaccines, it is becoming apparent that both the innate and adaptive immune systems must be stimulated to protect from the current and future recognition of the target antigen. Further, vaccine formulation in a delivery system that has high patient acceptability, which stabilizes the vaccine and promotes cost-effective delivery, is essential for long-term use. Vaccine stability can be improved by optimizing the composition of formulations by the addition of excipients, thus, restricting molecular mobility and preventing degradation. This Special Issue focuses on the different platforms that are available for developing robust immunotherapies for use as vaccine candidates, along with vaccine stabilizations such as lyophilization, spray drying, nanoparticles, lipid vesicles, etc., and their subsequent delivery via various routes of administration.

We encourage your submission and note that there is a short turnaround time for publication.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)